Impact of HPV mRNA types 16, 18, 45 detection on the risk of CIN3+ in young women with normal cervical cytology.

We are excited to share the new article by Al-Shibli et al.

The presented data for the 3-type HPV mRNA test, PreTect SEE, demonstrates that the expression of HPV mRNA 16, 18 and 45 represent a significant risk of future cervical abnormalities needing to be treated, even if the cytology is negative at the time of infection.

Screening young women with a 3-type HPV mRNA test can help avoid cervical cancers that may be missed when screening with cytology alone, while minimizing over referrals as opposed to screening by a 14-type HPV-DNA test.

Find out more information about how PreTect can help you to improve your cervical cancer screening here.